新辅助化疗对乳腺癌ki67、TopoⅡα表达的影响及其临床意义

Influence of Neoadjuvant Chemotherapy on the Expression of Ki-67 and Top Ⅱα in Breast Cancer and the Significance

【目的】评价新辅助化疗对乳腺癌患者Ki-67、TopoⅡα表达的影响及其临床预测价值。【方法】选择2009年3月至2012年3月乳腺外科收治的乳腺癌患者45例，采用免疫组织化学染色法检测新辅助化疗前后Ki-67、TopoⅡα的表达，并通过彩色超声测定乳腺癌原发灶体积。依据世界卫生组织（WTO）肿瘤缓解标准进行临床疗效评价。【结果145例患者，新辅助化疗总有效率为73．33％。化疗前后Ki67（71．1%vs48．9％）和TopoⅡα（57．8％vs33．3％）阳性率比较，其差异均有统计学意义（均P〈0．05）。【结论】新辅助化疗对乳腺癌患者临床疗效显著；并对肿瘤组织中的Ki67、TopoⅡα表达起下调作用。Ki67、TopoⅡα阳性的患者对新辅助化疗的敏感性更高。

[Objective] To evaluate the influence of neoadjuvant chemotherapy on the expression of Ki 67 and TopoⅡα and clinical predictive value. [[Methods] A total of 45 patients with breast cancer in breast surgery department from March 2009 to March 2012 were chosen. Immunohistochemical staining method was used to detect the expression of Ki67 and TopoⅡα before and after neoadjuvant chemotherapy. Primary tumor volume was measured by color Doppler ultrasound. Tumor remission standard of world health organization（WTO） was used to assess clinical efficacy. [Results]Total effective rate of neoadjuvant chemotherapy in 45 patients was 73.33 %. Therewas significant difference in the positive rate of Ki67（71.1% vs 48.9%） and TopoⅡα（57.8% vs 33.3%） between before and after chemotherapy（all P 〈0.05）. [Conclusion] Neoadjuvant chemotherapy is significantly effective for breast cancer patients, and can decrease the expression of Ki67 and TopoⅡα in tumor tissue. Patients with posi- tive expression of Ki67 and TopoⅡα are higher sensitivity to neoadjuvant chemotherapy.